2026 Compensation Guide

2026 Pharmacovigilance Manager Compensation Guide

Pharmacovigilance leaders own drug safety reporting, signal detection, aggregate report authorship (PSUR/PBRER, DSUR), and regulatory inspection readiness. In 2026 demand is elevated at clinical-stage and commercial-stage biotech alike.

Request Calibrated Salary Data Pharmacovigilance Recruiters

Written by Darren NelsonReviewed by Recruits Lab Research TeamUpdated 2026

Direct Answer

What does a pharmacovigilance manager make in 2026?

U.S. pharmacovigilance compensation in 2026: Manager $145K-$195K base, Senior Manager $180K-$240K, Director $220K-$300K, Senior Director $270K-$340K, VP PV $310K-$380K+. Bonuses run 15-30 percent of base. Equity at venture-backed biotech ranges from 0.02% to 0.30%.

Compensation data is directional and may vary based on geography, company stage, industry, equity, bonus structure, and candidate experience. This guide is an educational resource, not a definitive compensation survey.

Compensation Bands

Base, bonus, and equity by level. All figures are 2026 U.S. directional ranges.

Level	Base Salary	Bonus / OTE	Equity	Notes
PV Manager	$145K-$195K	15-20% ($25K-$40K)	0.02%-0.06%	Owns case processing oversight and aggregate report sections.
Senior PV Manager	$180K-$240K	15-25% ($30K-$60K)	0.04%-0.10%	Manages PV vendor and authors aggregate reports end-to-end.
Director PV	$220K-$300K	20-30% ($50K-$90K)	0.06%-0.18%	Functional ownership at clinical-stage biotech. Inspection lead.
Senior Director PV	$270K-$340K	25-30% ($75K-$110K)	0.10%-0.25%	Multi-program PV oversight. Reports to VP or CMO.
VP Pharmacovigilance	$310K-$380K+	30-40% ($110K-$160K+)	0.15%-0.30%	Departmental ownership. PV Qualified Person responsibilities.

Bonus Structure

PV bonuses follow standard biotech grids (15-30 percent target). VP-level PV roles add inspection readiness and regulatory submission milestones to bonus criteria.

Equity Structure

PV equity grants at venture-backed biotech are smaller than R&D peers but include refresh grants at 24 months. Late-stage clinical and commercial-stage biotechs increasingly compete for VP PV talent with elevated grants.

Geographic Comparisons

Market	vs. Baseline	Commentary
Boston / Cambridge	1.00x (baseline)	Deepest PV talent pool. Most clinical and commercial biotechs hiring.
San Francisco Bay Area	0.98x-1.05x	Strong demand. Slight premium at Director+ for inspection-ready candidates.
New York / NJ	0.95x-1.05x	Anchored by big pharma PV alumni pool.
Research Triangle (NC)	0.90x-0.98x	Strong CRO ecosystem source for PV talent.
Remote (US)	0.92x-1.00x	Common. PV roles are highly remote-compatible.

Hiring Market Commentary

1
PV hiring accelerated in 2025 as commercial-stage approvals expanded and clinical-stage biotechs hired Director PV earlier in development.
2
PV Qualified Person (EU QPPV) experience commands a 10-20 percent premium for U.S.-based roles supporting EU programs.
3
Argus, ARISg, and Veeva Vault Safety experience are differentiators at the Manager and Senior Manager level.

Talent Availability

Tight

PV Managers are moderately available. Director and Senior Director PV with both clinical and commercial experience are tight. VP PV with QPPV experience is very tight.

Market Indicators

●Average time-to-hire Director PV: 10-14 weeks
●Inspection readiness experience required by 80 percent of Director+ searches
●EU QPPV experience: top differentiator for VP-level placements

Recruits Lab Hiring Insights

Patterns we have observed across recent placements in this market.

Our 2024-2026 PV placements close 1.6x faster when the hiring biotech can articulate a 3-year PV roadmap during first interviews.
Big-pharma PV alumni transitioning to clinical-stage biotech are our highest-volume Director PV source in 2025-2026.
Remote-eligible Senior Manager and Director PV searches close 25-30 percent faster than on-site equivalents.

Frequently Asked Questions

When does a biotech hire its first Director of Pharmacovigilance?+

Most clinical-stage biotechs hire a dedicated PV leader between Phase 1 enrollment and Phase 2 readout, when case volume and aggregate reporting commitments grow materially.

What does a VP Pharmacovigilance earn at a commercial-stage biotech?+

$310K-$380K+ base in 2026, plus 30-40 percent bonus and 0.15-0.30 percent equity at venture-backed companies. Public commercial-stage biotechs pay similar cash with RSUs in place of options.

Is pharmacovigilance work remote-friendly?+

Yes. Most Manager through Director PV roles allow primary remote with quarterly site travel. VP PV roles increasingly allow remote, though some require hybrid at HQ.